Dearborn Partners LLC increased its stake in Gilead Sciences Inc. The fund owned 198,661 shares of the biopharmaceutical company’s stock after buying an additional 15,761 shares during the period. EXACT Sciences Corporation has an EPS ratio of -1.82.
Advertisement
Several other hedge funds also recently modified their holdings of GILD. The company finished it is trading at $18.64. Blue Edge Capital LLC raised its stake in Gilead Sciences by 0.7% in the fourth quarter. PacWest Financial Management Inc raised its stake in Gilead Sciences by 0.7% in the first quarter.
Gilead Sciences Inc. has a 52-week low of $76.67 and a 52-week high of $113.31. GILD has logged a 50-day moving average of $81.12 and 200-day moving average of $86.86.
Gilead Sciences Inc.’s (GILD) made a return of -3.61%% in one month through last close, displaying a -11.73% return during the past three months. 22 analysts have rated the company as a strong “Hold”. The business’s revenue was down 5.7% compared to the same quarter past year.
During last 3 month it remained at -11.73%.
Analysts’ mean recommendation for Gilead Sciences Inc.’s (GILD) stands at 2.20. It has a dividend yield of 2.45%.
Gilead Sciences, Inc. had its “hold” rating reiterated by analysts at Jefferies. Leerink Swann reissued an “outperform” rating and issued a $112.00 target price (down previously from $114.00) on shares of Gilead Sciences in a report on Wednesday, August 24th.
The sell-side experts examining the company’s fundamentals have put a price target of $108.75 on the stock. The average target stock price is $111.05 with seven analysts rating the stock a strong buy, nine firms rating the company a buy, nine firms rating the stock a hold, 0 rating the company to underperform, and finally 0 brokerages rating the company as sell. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $106.74.
Advertisement
08/30/2016 – Gilead Sciences, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. Following the transaction, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Its Director Lofton Kevin E sold 3,500 company shares for $286000.9, in a transaction on 2016-08-24. This transaction occurred on 2016-08-01 totals $8050000. The disclosure for this sale can be found here. Gilead Sciences Inc.’s (GILD) is a part of Healthcare sector and belongs to Biotechnology industry. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera.
